# Melanotan I versus melanotan II Canonical: https://europeanpeptideshop.com/blog/melanotan-i-vs-ii/ Explore the catalogue and research library. Ordering and shipping have not opened yet. Comparisons · 8 November 2026 · 3 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/) ### On this page ## The short answer Melanotan I and Melanotan II are both synthetic analogues of alpha-melanocyte-stimulating hormone. They were made in the same Arizona laboratory and they share a name. In structure, receptor selectivity and regulatory history they are different molecules. Property | Melanotan I | Melanotan II Other names | Afamelanotide, [Nle4, D-Phe7]-alpha-MSH | MT-2, MT-II Structure | Linear, 13 residues | Cyclic, 7 residues, lactam bridge Molecular weight | About 1647 Da | About 1024 Da Receptor profile | MC1R-preferring | MC1R, MC3R, MC4R, MC5R Licensed anywhere | Yes, as Scenesse (implant) | No ## Structure Melanotan I keeps the full length of the natural hormone and makes two substitutions: norleucine for methionine at position 4 and D-phenylalanine for L-phenylalanine at position 7. These two changes make it far more stable than alpha-MSH while leaving the linear chain intact. Melanotan II goes further. It cuts the chain down to the core residues that bind the receptor and closes them into a ring with a lactam bridge. A shorter, rigid ring binds more tightly and survives longer, and it also loses the selectivity that the longer chain carries. ## Receptor selectivity This is the difference that matters pharmacologically. Melanotan I acts mainly at MC1R, the receptor on melanocytes. Melanotan II acts at MC1R and also at MC3R, MC4R and MC5R, which are found in the brain and in other tissues. The reported effects of the two peptides in animal and early human studies differ accordingly, and so do the adverse events reported for each. The full receptor table is on the [Melanotan II identity page](https://europeanpeptideshop.com/blog/melanotan-2/). ## Regulatory history Afamelanotide, the pharmaceutical name for Melanotan I, was taken through clinical development by Clinuvel and holds a marketing authorisation in the EU and the UK as Scenesse, a subcutaneous implant indicated for adults with erythropoietic protoporphyria. That is a specific product, strength and indication, and it describes nothing about a research vial. Melanotan II was studied in the 1990s and was not taken to authorisation. It has no licensed product anywhere. Its metabolite bremelanotide was developed as a separate medicine. ## "Which is better" is the wrong question The phrase appears in the search data, usually with "reddit" attached. For a laboratory, neither is better. They are two reagents with different receptor profiles, and the choice depends on which receptor question is being asked. For anyone considering them for personal use, both are unlicensed for that purpose in the UK, and the MHRA has warned specifically about melanotan products. The catalogue item is the [Melanotan II 10mg](https://europeanpeptideshop.com/shop/melanotan-ii-10mg/) research vial, with a batch certificate in the [COA publication status](https://europeanpeptideshop.com/coa/). Melanotan I is not currently listed. Reports of adverse events associated with unlicensed Melanotan II products are summarised in [Melanotan II adverse effects](https://europeanpeptideshop.com/blog/melanotan-2-side-effects/). ## EPS documentation Use the [research catalogue](https://europeanpeptideshop.com/shop/) to check the exact name, labelled amount and format. The [COA library](https://europeanpeptideshop.com/coa/) publishes the original Janoshik reports selected for EPS, retaining the original report client name and any missing batch fields. Literature findings and another supplier's analytical results are not evidence about an EPS batch. ## Laboratory research only Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here. ## References - [EMA: Scenesse, afamelanotide product assessment](https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse) ## More articles Compound research · 2 min read ## [Melanotan II adverse-effect reports](https://europeanpeptideshop.com/blog/melanotan-2-side-effects/) The adverse events reported in early studies and in case reports of unlicensed Melanotan II use, with the evidence tier of each, and what cannot be. 8 November 2026 Compound research · 3 min read ## [Melanotan II research explained](https://europeanpeptideshop.com/blog/melanotan-2/) What Melanotan II is, how it relates to alpha-MSH, which melanocortin receptors it binds, and why it has never been a licensed medicine anywhere. 8 November 2026 Comparisons · 4 min read ## [5-Amino-1MQ versus SLU-PP-332](https://europeanpeptideshop.com/blog/5-amino-1mq-vs-slu-pp-332-nnmt-err-research/) Compare 5-Amino-1MQ and SLU-PP-332 in plain English: different small molecules, different targets and the limits of metabolic research claims. 8 November 2026